Loading...
XNAS
AUPH
Market cap1.20bUSD
Jul 16, Last price  
8.85USD
1D
-1.56%
1Q
14.19%
Jan 2017
321.43%
IPO
-92.78%
Name

Aurinia Pharmaceuticals Inc

Chart & Performance

D1W1MN
P/E
207.87
P/S
5.09
EPS
0.04
Div Yield, %
Shrs. gr., 5y
9.46%
Rev. gr., 5y
274.78%
Revenues
235m
+33.97%
1,177,8883,522,6492,334,6463,876,7464,052,1443,420,452927,5226,157,836948,561278,000235,000173,000420,000463,000318,00050,118,00045,605,000134,030,000175,513,000235,133,000
Net income
6m
P
000000000-16,647,000-18,607,000-23,295,000-70,792,000-64,120,000-123,846,000-102,680,000-180,966,000-108,180,000-78,020,0005,752,000
CFO
44m
P
000000000-16,904,000-17,766,000-18,713,000-41,169,000-51,610,000-63,456,000-69,858,000-157,692,000-79,529,000-33,461,00044,388,000
Earnings
Jul 30, 2025

Profile

Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops and commercializes therapies to treat various diseases in the United States and China. It is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. The company is headquartered in Victoria, Canada.
IPO date
Jul 16, 2001
Employees
300
Domiciled in
CA
Incorporated in
CA

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
235,133
33.97%
175,513
30.95%
134,030
193.89%
Cost of revenue
221,061
258,825
247,023
Unusual Expense (Income)
NOPBT
14,072
(83,312)
(112,993)
NOPBT Margin
5.98%
Operating Taxes
1,696
551
1,828
Tax Rate
12.05%
NOPAT
12,376
(83,863)
(114,821)
Net income
5,752
-107.37%
(78,020)
-27.88%
(108,180)
-40.22%
Dividends
Dividend yield
Proceeds from repurchase of equity
(40,239)
2,433
BB yield
3.07%
-0.40%
Debt
Debt current
15,072
31,196
936
Long-term debt
143,666
179,616
15,240
Deferred revenue
Other long-term liabilities
11,107
10,911
12,166
Net debt
(199,738)
(139,878)
(373,214)
Cash flow
Cash from operating activities
44,388
(33,461)
(79,529)
CAPEX
(281)
(718)
(292)
Cash from investing activities
39,262
(6,706)
(60,632)
Cash from financing activities
(49,092)
(5,130)
2,433
FCF
53,629
(220,859)
(113,577)
Balance
Cash
358,476
350,489
389,390
Long term investments
201
Excess cash
346,719
341,914
382,688
Stockholders' equity
250,479
257,166
319,946
Invested Capital
217,475
244,904
105,118
ROIC
5.35%
ROCE
3.01%
EV
Common stock shares outstanding
146,194
143,236
141,915
Price
8.98
-0.11%
8.99
108.10%
4.32
-81.11%
Market cap
1,312,822
1.95%
1,287,692
110.04%
613,073
-79.28%
EV
1,113,084
1,147,814
239,859
EBITDA
20,786
(71,665)
(110,287)
EV/EBITDA
53.55
Interest
4,835
2,775
5,118
Interest/NOPBT
34.36%